Lilly

Company expects no shortage of U.S. supplies of products manufactured from its Sesto Fiorentino Italy plant that was the subject of a May 28 FDA warning letter. During a February 1-5 inspection, the agency found deficiencies in both aseptic processing areas and media fill procedures. The Lilly plant manufactures Mandol (cefamandole nafate), Keflin (cephalothin sodium), Ketzol (cefazolin sodium) and Kefurox (cefuroxime sodium)